Xydalba 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0043 
C.I.6.a - Change(s) to therapeutic indication(s) - 
13/10/2022 
09/12/2022 
SmPC and PL 
Please refer to the Scientific Discussion ‘Xydalba-H-C-
Addition of a new therapeutic indication or 
modification of an approved one 
002840-II-0043’ 
IA/0046 
B.II.b.3.a - Change in the manufacturing process of 
24/06/2022 
n/a 
the finished or intermediate product - Minor change 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
in the manufacturing process 
T/0045 
Transfer of Marketing Authorisation 
29/04/2022 
13/06/2022 
SmPC, 
Labelling and 
PL 
IA/0044/G 
This was an application for a group of variations. 
04/02/2022 
n/a 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
N/0042 
Minor change in labelling or package leaflet not 
11/10/2021 
13/06/2022 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10350
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
/202011 
dalbavancin 
IA/0041 
A.7 - Administrative change - Deletion of 
03/03/2021 
n/a 
manufacturing sites 
IAIN/0039/G 
This was an application for a group of variations. 
25/01/2021 
19/10/2021 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
Page 2/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II/0037 
C.I.13 - Other variations not specifically covered 
14/01/2021 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IB/0038 
C.I.z - Changes (Safety/Efficacy) of Human and 
26/10/2020 
19/10/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0035/G 
This was an application for a group of variations. 
23/10/2020 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
IA/0036/G 
This was an application for a group of variations. 
02/10/2020 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.III.2.a.2 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - Excipient/AS starting material 
Page 3/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10350
Periodic Safety Update EU Single assessment - 
11/06/2020 
n/a 
PRAC Recommendation - maintenance 
/201911 
dalbavancin 
IA/0034 
B.II.b.2.a - Change to importer, batch release 
20/05/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
IA/0033 
B.II.b.2.a - Change to importer, batch release 
20/05/2020 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
N/0030 
Minor change in labelling or package leaflet not 
18/02/2020 
19/10/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0031 
C.I.11.z - Introduction of, or change(s) to, the 
17/02/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
R/0028 
Renewal of the marketing authorisation. 
19/09/2019 
05/12/2019 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Xydalba in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IA/0029 
B.II.b.2.a - Change to importer, batch release 
13/11/2019 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 4/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10350
Periodic Safety Update EU Single assessment - 
14/06/2019 
n/a 
PRAC Recommendation - maintenance 
/201811 
dalbavancin 
IAIN/0027/G 
This was an application for a group of variations. 
12/03/2019 
31/07/2019 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
IB/0025 
B.I.b.1.z - Change in the specification parameters 
17/12/2018 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IB/0024 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/12/2018 
31/07/2019 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IAIN/0023/G 
This was an application for a group of variations. 
01/08/2018 
31/07/2019 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
II, Labelling 
and PL 
Page 5/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not including batch control/testing 
PSUSA/10350
Periodic Safety Update EU Single assessment - 
14/06/2018 
n/a 
PRAC Recommendation - maintenance 
/201711 
dalbavancin 
IA/0020 
B.II.b.5.z - Change to in-process tests or limits 
18/01/2018 
n/a 
applied during the manufacture of the finished 
product - Other variation 
PSUSA/10350
Periodic Safety Update EU Single assessment - 
30/11/2017 
n/a 
PRAC Recommendation - maintenance 
/201705 
dalbavancin 
IB/0018/G 
This was an application for a group of variations. 
08/11/2017 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
Page 6/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
batch control/testing takes place 
IA/0019 
B.I.a.2.a - Changes in the manufacturing process of 
27/09/2017 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/10350
Periodic Safety Update EU Single assessment - 
09/06/2017 
n/a 
PRAC Recommendation - maintenance 
/201611 
dalbavancin 
N/0016 
Minor change in labelling or package leaflet not 
17/03/2017 
31/07/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
T/0014 
Transfer of Marketing Authorisation 
16/12/2016 
27/01/2017 
SmPC, 
Labelling and 
PL 
IB/0013 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
01/12/2016 
27/01/2017 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
PSUSA/10350
Periodic Safety Update EU Single assessment - 
01/12/2016 
n/a 
PRAC Recommendation - maintenance 
/201605 
dalbavancin 
IB/0011 
C.I.11.z - Introduction of, or change(s) to, the 
31/08/2016 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0010 
B.I.b.2.a - Change in test procedure for AS or 
11/07/2016 
n/a 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 7/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0009 
Minor change in labelling or package leaflet not 
22/06/2016 
27/01/2017 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/10350
Periodic Safety Update EU Single assessment - 
09/06/2016 
n/a 
PRAC Recommendation - maintenance 
/201511 
dalbavancin 
IA/0007/G 
This was an application for a group of variations. 
25/04/2016 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
N/0008 
Update of the package leaflet with revised contact 
22/04/2016 
27/01/2017 
PL 
details of the local representatives for Hungary and 
Slovenia. The MAH also took the opportunity to make 
corrections to some of the local representatives 
contact details in the Spanish, Greek, Croatian, 
Hungarian, Icelandic, Lithuanian, Slovakian and 
Slovenian package leaflets in line with the English 
texts. 
Minor change in labelling or package leaflet not 
connected with the SPC (Art. 61.3 Notification) 
II/0004 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
28/01/2016 
02/03/2016 
SmPC and PL 
new quality, preclinical, clinical or pharmacovigilance 
data 
Page 8/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10350
Periodic Safety Update EU Single assessment - 
03/12/2015 
n/a 
PRAC Recommendation - maintenance 
/201505 
dalbavancin 
II/0003 
C.I.13 - Other variations not specifically covered 
24/09/2015 
n/a 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
IAIN/0001 
C.I.8.a - Introduction of or changes to a summary of 
28/04/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
N/0002 
Minor change in labelling or package leaflet not 
17/04/2015 
02/03/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 9/9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
